Van DyneEAHenleySJSaraiyaM, et al. Trends in human papillomavirus–associated cancers—United States, 1999-2015. MMWR Morbid Mortal Wkly Rep2018;67(33):918-24.
GarlandSMKjaerSKMuñozN, et al. Impact and effectiveness of the quadrivalent human papillomavirus vaccine: a systematic review of 10 years of real-world experience. Clin Infect Dis2016;63(4):519-27.
6.
ChecchiMMesherDMohammedHSoldanK.Declines in anogenital warts diagnoses since the change in 2012 to use the quadrivalent HPV vaccine in England: data to end 2017. Sex Transm Infect2019;95(5):368-73.
7.
PalmerTWallaceLPollockKG, et al. Prevalence of cervical disease at age 20 after immunisation with bivalent HPV vaccine at age 12-13 in Scotland: retrospective population study. BMJ2019;365:l1161.
8.
InnesCRHWillimanJÁSimcockBJ, et al. Impact of human papillomavirus vaccination on rates of abnormal cervical cytology and histology in young New Zealand women. NZ Med J2020;133(1508):72-84.
9.
BrotonsMMonfilLRouraE, et al. Impact of a single-age cohort human papillomavirus vaccination strategy in Catalonia, Spain: population-based analysis of anogenital warts in men and women. Prev Med2020;138:106166.
10.
GuoF.CofieLEBerensonAB.Cervical cancer incidence in young U.S. females after human papillomavirus vaccine introduction. Am J Prev Med2018;55(2):197-204.
11.
LuostarinenTApterDDillnerJ, et al. Vaccination protects against invasive HPV-associated cancers. Int J Cancer2018;142(10):2186-7.
12.
LeiJPlonerAElfströmKM, et al. HPV vaccination and the risk of invasive cervical cancer. N Engl J Med2020;383(14):1340-8.
13.
HallMTSimmssKTLewJ-B, et al. The projected timeframe until cervical cancer elimination in Australia: a modelling study. Lancet Public Health2019;4(1):E19-E27.
14.
GlazierRHGreenMEYuFC, et al. Shifts in office and virtual primary care during the early COVID-19 pandemic in Ontario, Canada. CMAJ2021;193:E200-10.